Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to 70 Years; BMI ≥24 required; non-obese participants included; conditions: Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
- Interventions
- GLP-1 Receptor Agonists
- Conditions
- Type 2 Diabetes; Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)
- Phase and size
- Phase 4 · 60 participants
- Dates
- Start 2026-04-01
Primary completion 2028-03-30 - Sponsor
- The First Affiliated Hospital with Nanjing Medical University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- heart rate variability（HRV）baseline and 12 weeks later]
02Eligibility
Who can take part
Inclusion Criteria: * Patients aged 18-70 years * Patients with type 2 diabetes mellitus (T2DM) who meet the diagnostic guidelines * Patient has signed the relevant informed consent form * Being overweight or obese (BMI ≥ 24 kg/m²) Exclusion Criteria: * Age \< 18 years * Pregnant or lactating women * Acute or chronic pancreatitis * Recent acute complications of diabetes (e.g., diabetic ketoacidosis, hyperosmolar hyperglycemic state) * Arrhythmia or taking medications that affect heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers, antiarrhythmic drugs) * Thyroid disease * Severe organ dysfunction (e.g., heart, liver, kidney failure) * Denial of informed consent
03Change log
Registry changes
No changes recorded since the trial was added.